Medical device companies raised a total of $1.1 billion during the first quarter of 2012, a 40% increase over Q4 2011’s $800 million, and a much stronger start to the year than 2011’s opening quarter of $732 million. (See Exhibit 1.)
Exhibit 1
Medical device companies raised $1.1 billion, a 40% increase over Q4 2011’s $800 million. Two billion-dollar deals in the resuscitation market boosted device acquisition activity to $4.2 billion. Twenty diagnostics financings brought in a collective $302 million, soaring above the previous quarter’s $269 million. There were seven diagnostics M&A deals completed, totaling $589 million – down yet again.
Medical device companies raised a total of $1.1 billion during the first quarter of 2012, a 40% increase over Q4 2011’s $800 million, and a much stronger start to the year than 2011’s opening quarter of $732 million. (See Exhibit 1.)
Exhibit 1
Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.
Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.